Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy

Basit Öğe Kaydı
dc.authoridDemircan, Nazim/0000-0001-6630-5278
dc.authoridBeşiroğlu, Mehmet/0000-0002-1171-8320
dc.authoridalan, ozkan/0000-0002-6635-2012
dc.authoridOZTURK, MEHMET AKIF/0000-0003-1365-7944
dc.authoridYumuk, Perran Fulden/0000-0001-8650-299X
dc.authorwosidDemircan, Nazim/HHY-8715-2022
dc.authorwosidÖztürk, Mehmet/JFJ-3399-2023
dc.authorwosidBeşiroğlu, Mehmet/AEQ-3080-2022
dc.authorwosidalan, ozkan/AAV-5044-2020
dc.authorwosidOZTURK, MEHMET AKIF/C-2218-2013
dc.authorwosidYumuk, Perran Fulden/A-6189-2018
dc.contributor.authorDemircan, Nazim Can
dc.contributor.authorDane, Faysal
dc.contributor.authorOzturk, Mehmet Akif
dc.contributor.authorBabacan, Nalan Akgul
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorKaya, Serap
dc.contributor.authorErcelep, Ozlem
dc.date.accessioned2024-06-12T10:54:25Z
dc.date.available2024-06-12T10:54:25Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Colorectal cancer (CRC) is a significant cause of cancer mortality worldwide. Survival has improved with bevacizumab in metastatic CRC treatment. Our purpose was to analyse survival and prognostic factors in metastatic CRC patients treated with first-line bevacizumab-based treatment. Methods: Files of CRC patients were examined retrospectively and 360 patients treated with first-line bevacizumab were included. Objective response rates (ORRs), median progression-free and overall survival (PFS and OS) of the patients were calculated. Survival was analyzed with the Kaplan-Meier method. Log-rank test and Cox regression model were used for univariate and multivariate analyses, respectively. Results: Median age at diagnosis was 59.5 years. Of the patients 74.4% had initially stage IV disease. Median PFS was 8.5 months, median OS 25.3 months and overall response rate (ORR) 51.4%. ORRs, median PFS and OS of KRAS mutant and wild-type or unknown patients were statistically similar. In left-sided disease, median PFS and OS (9.6 and 27.1 months) were superior compared to right-sided disease (7.3 and 19.4 months) (p=0.005 and 0.02, respectively). Primary disease location, histopathologic grade, primary surgery and metastasectomy affected OS significantly. Histopathologic grade (hazard ratio=1.77, p=0.002) and metastasectomy (hazard ratio=0.48, p=0.001) were independent prognostic factors. Conclusions: Our study confirmed that after bevacizumab-based treatment, KRAS status might not be a prognostic factor. We have also shown that left CRCs have more favorable outcomes than right CRCs in bevacizumab therapy. Additionally, even in metastatic setting histopathologic grade of the primary CRC together with metastasectomy are independent prognostic factors.en_US
dc.identifier.endpage1500en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid31646797en_US
dc.identifier.startpage1494en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19051
dc.identifier.volume24en_US
dc.identifier.wosWOS:000481595900024en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectColorectal Canceren_US
dc.subjectPrognostic Factorsen_US
dc.subjectPrimary Tumor Resectionen_US
dc.subjectK-Ras Mutationen_US
dc.subjectColon-Canceren_US
dc.subjectCurative Resectionen_US
dc.subjectPhase-Iiien_US
dc.subjectFollow-Upen_US
dc.subjectStageen_US
dc.subjectChemotherapyen_US
dc.subjectOutcomesen_US
dc.subjectTrialen_US
dc.titleAssessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu